Blockchain Registration Transaction Record

Tryptamine Therapeutics Launches on ASX with Innovative Psilocin Formulation

Tryptamine Therapeutics Inc. (ASX: TYP) CEO discusses the company's start of trading on the Australian Securities Exchange (ASX) and its focus on developing intravenous-infused psilocin formulation for psychedelic-assisted therapy.

The news is significant as it highlights the growing interest in psychedelic-assisted therapy as a potential treatment for various disorders. The development of an intravenous-infused psilocin formulation by Tryptamine Therapeutics could offer a faster onset of the psychedelic state and precise control of the experience, making it commercially viable. The promising results from open-label trials also indicate the potential impact of these formulations on addressing conditions such as fibromyalgia, irritable bowel syndrome, and binge eating disorder.